There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. Identifying these diseases quickly and efficiently, where possible at the point of care, can be vital in maintaining a patient's quality of life. New drug modalities are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.
We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
The core focus of our business continues to be on innovation and the development of new markers with IP protection that will increase testing in the laboratory and point-of-care settings.
The company has successfully implemented its strategy of growth through the development and marketing of novel diagnostic tests in areas of clinical need since its inception and key products illustrating this include:
Further information is available in the Products section of this site
Additionally in line with our strategy, we are working on markers in a number of different clinical areas including:
Further information on these new assays is available in the Disease Areas section of the website
We have research centres in Norway and Scotland and more than 50 scientists are employed in this capacity.
We welcome discussion with organisations or individuals wishing to accelerate development, clinical evaluation and commercialisation of any novel markers with patent protection and potential clinical utility.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.